On January 22, 2013, ARCA biopharma, Inc. ("ARCA"), entered into a Subscription Agreement (the "Purchase Agreement") with various accredited investors in connection with a private placement of its common stock and warrants. Pursuant to the Purchase Agreement, ARCA agreed to sell and issue an aggregate of 2,138,580 shares of its common stock and warrants to purchase up to an additional 1,497,006 shares of its common stock at a purchase price of $0.4676 per unit, each unit consisting of a share of common stock and a warrant to purchase 0.70 shares of common stock. ARCA Director and Chief Executive Officer Dr. Michael Bristow participated for $500,000, along with other accredited investors.

The warrants to be issued pursuant to the Purchase Agreement (the "Warrants") will be exercisable immediately upon issuance and shall expire seven years from the date of issuance, and have an exercise price of $0.3801 per share, equal to 100% of the closing bid price of ARCA's common stock on the NASDAQ Capital Market on January 22, 2013.

ARCA anticipates raising gross proceeds of approximately $1,000,000 in connection with the private placement. The net proceeds, after deducting offering expenses, are expected to be approximately $850,000. ARCA will use the net proceeds from the private placement solely for general working capital purposes. The closing of the private placement is expected to take place on or about January 24, 2013, subject to customary closing conditions.

Under the terms of a Registration Rights Agreement (the "Rights Agreement") entered into at the closing of the transaction, ARCA will grant to the investors certain registration rights related to the shares of common stock to be sold in the private placement and the shares of common stock underlying the Warrants. ARCA will be required to file a registration statement for the resale of such shares of common stock and such shares of common stock underlying the Warrants, within 15 calendar days following the closing of the private placement and use its commercially reasonable efforts to cause such registration statement to be declared effective as soon as practicable but not later than 90 calendar days following the closing date (or the 120th calendar day after the closing date in the event that such registration statement is subject to review by the SEC). ARCA has agreed to other customary obligations regarding registration, including indemnification and maintenance of the registration statement.

Dawson James Securities, Inc. ("Dawson") acted as exclusive placement agent for the Company in the transaction. Pursuant to its engagement agreement with the Company, Dawson will receive a fee for its services in the transaction equal to 6% of the gross financing proceeds received by the Company. In addition, the Company will issue to Dawson James warrants to purchase up to 10% of the total number of shares issued to investors in the transaction on the same terms as the Warrants. Dawson will also be reimbursed by the Company for its expenses in an amount up to $10,000.

The foregoing is only a brief description of the material terms of the Purchase Agreement, Rights Agreement and the Warrants and does not purport to be a complete description of the rights and obligations of the parties thereunder. The foregoing is qualified in its entirety by reference to the form of Purchase Agreement, the form of Rights Agreement and form of Warrant, which are filed as Exhibits 10.1, 10.2 and 4.1, respectively, to this Current Report on Form 8-K, which are incorporated by reference herein.

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02. The Company believes that each of the investors under the Purchase Agreements are "accredited investors," and the issuance of the shares of common stock pursuant to the Purchase Agreements and the Warrants will therefore be made pursuant to an exemption from the registration requirements under Section 4(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated thereunder. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state

(d) Exhibits.

Exhibit Number         Description

4.1                    Form of Warrants to Purchase Shares of Common Stock

10.1                   Form of Subscription Agreement by and among the Company and
                       the purchasers identified therein, dated January 22, 2013

10.2                   Form of Registration Rights Agreement